ArticleInfectious diseases of poverty2014
Development of antimalarial drugs and their application in China: a historical review.
Article in Infectious diseases of poverty, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- A review of the effects of artemether-lumefantrine on gametocyte carriage and disease transmission.Malaria journal · 2014Pooled it
- Piperaquine Monotherapy of Drug-Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia.The Journal of infectious diseases · 2016Trial
- Phenotypic Analysis of the Anti-Molecules (Basel, Switzerland) · 2026Article
- Medicinal plants traditionally used for management of malaria in rural communities of Uganda.BMC complementary medicine and therapies · 2025Article
- Pyronaridine: a review of its clinical pharmacology in the treatment of malaria.The Journal of antimicrobial chemotherapy · 2023Review
- Geographical origin of Plasmodium vivax in the Hainan Island, China: insights from mitochondrial genome.Malaria journal · 2023Article
- Artemisinin-Type Drugs in Tumor Cell Death: Mechanisms, Combination Treatment with Biologics and Nanoparticle Delivery.Pharmaceutics · 2022Review
- Evidence for the early emergence of piperaquine-resistant Plasmodium falciparum malaria and modeling strategies to mitigate resistance.PLoS pathogens · 2022Article
- Seven decades towards malaria elimination in Yunnan, China.Malaria journal · 2021Review
- Re-Envisioning Anti-Apicomplexan Parasite Drug Discovery Approaches.Frontiers in cellular and infection microbiology · 2021Review
- A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.International journal of antimicrobial agents · 2020Review
- Unsymmetrical Bisquinolines with High Potency againstMolecules (Basel, Switzerland) · 2020Article
- Recent Advances in the Discovery of Novel Antiprotozoal Agents.Molecules (Basel, Switzerland) · 2019Review
- Surveillance of Antimalarial Resistance Pfcrt, Pfmdr1, and Pfkelch13 Polymorphisms in African Plasmodium falciparum imported to Shandong Province, China.Scientific reports · 2018Article
- Progress in the Optimization of 4(1Chimia · 2017Article
- Prolonged parasite clearance in a Chinese splenectomized patient with falciparum malaria imported from Nigeria.Infectious diseases of poverty · 2017Article
- Initiation of gametocytogenesis at very low parasite density in Plasmodium falciparum infection.The Journal of infectious diseases · 2017Article
- Domestic trends in malaria research and development in China and its global influence.Infectious diseases of poverty · 2017Article
- Major parasitic diseases of poverty in mainland China: perspectives for better control.Infectious diseases of poverty · 2016Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This historical review covers antimalarials developed in China, which include artemisinin, artemether, artesunate, and dihydroartemisinin, as well as other synthetic drugs such as piperaquine, pyronaridine, benflumetol (lumefantrine), and naphthoquine. The curative effects of these antimalarials in the treatment of falciparum malaria, including chloroquine-resistant strain, are especially discussed. Following the World Health Organization (WHO) recommended artemisinin-based combination therapy (ACT), different combinations of artemisinin, or its derivative, along with another antimalarial drug were orally used to treat Plasmodium falciparum infections. The recrudescence rates were low, gametocyte carriers lessened, and the curative rate increased remarkably. The combination therapy effectively deferred the emergence of drug resistance in the parasite. The regulation "The guidelines and regimens for the use of antimalarial drugs in China" was issued to guide rational application and standardize malaria treatment in the country. As the recommended first-line drug to treat falciparum malaria in the world, ACT was adopted in the regulation. In response to the global initiative of malaria eradication proposed by the UN Millennium Development Goals (MDGs), the Chinese government has set a target to eliminate malaria by 2020.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.